A more refined approach targets the metabolic enzyme nicotinamide N-methyltransferase (NNMT), whose over-expression in CAFs and cancer cells depletes nicotinamide (vitamin B3) and the methyl donor S-adenosylmethionine (SAM), would achieve epigenome reshaping to sustain a pro-tumoral niche 200. This evidence concerns the gene NNMT and cancer.